ChiCTR2600117995 版本V1.0 版本创建时间2026/01/30 17:04:05 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600117995 

最近更新日期:

Date of Last Refreshed on:

2026-01-30 17:03:59 

注册时间:

Date of Registration:

2026-01-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

近视患者泪液与尿液中肾上腺素类物质的含量分析

Public title:

Analysis of Adrenaline-like Substances in Tear and Urine of Myopic Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

近视患者泪液与尿液中肾上腺素类物质的含量分析

Scientific title:

Analysis of Adrenaline-like Substances in Tear and Urine of Myopic Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杜显丽 

研究负责人:

杜显丽 

Applicant:

Qingdao Eye Hospital Affiliated to Shandong First 

Study leader:

Xianli Du 

申请注册联系人电话:

Applicant telephone:

+86 532 8589 9231

研究负责人电话:

Study leader's
telephone:

+86 532 8589 9231

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lilibestever@126.com

研究负责人电子邮件:

Study leader's E-mail:

lilibestever@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市燕儿岛路5号

研究负责人通讯地址:

山东省青岛市市南区燕儿岛路5号

Applicant address:

5 Yanerdao Road, Qingdao City, Shandong Province, China

Study leader's address:

NO.5 Yan’erdao Road, 266071, Qingdao

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第一医科大学附属青岛眼科医院

Applicant's institution:

Qingdao Eye Hospital Affiliated to Shandong First Medical University

研究负责人所在单位:

山东第一医科大学附属青岛眼科医院

Affiliation of the Leader:

QINGDAO EYE HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

青眼伦审(快)[2025]55

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qingdao Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-02 00:00:00

伦理委员会联系人:

杨丰蔚

Contact Name of the ethic committee:

Yang FengYu

伦理委员会联系地址:

山东省青岛市市南区燕儿岛路5号

Contact Address of the ethic committee:

NO.5 Yan’erdao Road, 266071, Qingdao

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 532 8589 9231

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yangfengwei2015@163.com

研究实施负责(组长)单位:

山东第一医科大学附属青岛眼科医院

Primary sponsor:

QINGDAO EYE HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY

研究实施负责(组长)单位地址:

山东省青岛市市南区燕儿岛路5号

Primary sponsor's address:

NO.5 Yan’erdao Road, 266071, Qingdao

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东第一医科大学附属青岛眼科医院

具体地址:

山东省青岛市市南区燕儿岛路5号

Institution
hospital:

QINGDAO EYE HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY

Address:

NO.5 Yan’erdao Road, 266071, Qingdao

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

研究疾病:

近视  

Target disease:

Myopia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究旨在通过高效液相色谱质谱分析技术,定量检测近视患者与健康对照组的泪液及尿液样本中肾上腺素类物质的浓度差异。通过分析这些物质含量与近视度数、眼轴长度等临床参数的相关性,探索交感神经系统在近视发生发展中的作用,并为未来近视的早期筛查或干预提供理论支持。  

Objectives of Study:

This study aims to quantitatively detect the concentration differences of adrenaline-like substances in tear and urine samples between myopic patients and healthy controls using high-performance liquid chromatography-mass spectrometry (HPLC-MS). By analyzing the correlation between the levels of these substances and clinical parameters—such as myopic diopter and axial length—this research explores the role of the sympathetic nervous system in the development of myopia, providing theoretical support for future early screening or clinical intervention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.诊断为近视,并按等效球镜度数(SE)100-600度近视的患者; 2.?愿参加研究并签署知情同意书(需监护?签字)

Inclusion criteria

1.Patients diagnosed with myopia, with a spherical equivalent (SE) ranging from -1.00 D to -6.00 D; 2. Voluntarily participate in the study and sign the informed consent form (guardian signature required)

排除标准:

1.合并其他眼部疾病(如青光眼、白内障、视网膜病变等);
2.近期(3个月内)使用可能影响肾上腺素水平的药物(如β受体阻滞剂、抗抑郁药等);
3.全身性疾病(如高血压、糖尿病、甲状腺功能异常等);
4.进行近视矫正手术或其他干预措施。

Exclusion criteria:

1.Complication with other ocular diseases (e.g., glaucoma, cataract, and retinopathy);
2.Recent use (within the past 3 months) of medications that may affect adrenaline levels (e.g., $\beta$-blockers, antidepressants);
3.Systemic diseases (e.g., hypertension, diabetes mellitus, and thyroid dysfunction).
4.history of refractive surgery or other clinical interventions for myopia correction.

研究实施时间:

Study execute time:

From 2026-01-31 00:00:00 To 2026-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-31 00:00:00 To 2026-03-01 00:00:00

干预措施:

Interventions:

组别:

高度近视组

样本量:

50

Group:

High Myopia Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

低度近视组

样本量:

50

Group:

low Myopia Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东第一医科大学附属青岛眼科医院 

单位级别:

三级甲等 

Institution
hospital:

QINGDAO EYE HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

去甲肾上腺素含量

指标类型:

主要指标

Outcome:

Norepinephrine content

Type:

Primary indicator

测量时间点:

当次

测量方法:

质谱分析

Measure time point of outcome:

The present visit

Measure method:

Mass Spectrometry

指标中文名:

等效球镜度数

指标类型:

主要指标

Outcome:

Spherical Equivalent, SE

Type:

Primary indicator

测量时间点:

当次

测量方法:

电脑验光

Measure time point of outcome:

The present visit

Measure method:

Autorefraction

指标中文名:

眼轴长度

指标类型:

主要指标

Outcome:

Axial length, Al

Type:

Primary indicator

测量时间点:

当次

测量方法:

眼轴测量

Measure time point of outcome:

The present visit

Measure method:

Ocular Biometry

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

泪液

组织:

Sample Name:

tear

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 15 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

edc

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-01-30 17:03:59